ChengDa Pharmaceuticals Co., Ltd. (SHE:301201)
China
· Delayed Price · Currency is CNY 42.61
-0.14 (-0.33%)
Mar 9, 2026, 4:00 PM EDT
ChengDa Pharmaceuticals Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Market Capitalization | 6,454 | 3,057 | 3,934 | 4,912 | - | - | Upgrade
|
| Market Cap Growth | 116.40% | -22.31% | -19.91% | - | - | - | Upgrade
|
| Enterprise Value | 5,532 | 1,875 | 2,523 | 3,463 | - | - | Upgrade
|
| Last Close Price | 42.61 | 20.00 | 24.93 | 30.90 | - | - | Upgrade
|
| PE Ratio | - | - | 43.24 | 46.13 | - | - | Upgrade
|
| PS Ratio | 17.24 | 9.18 | 9.50 | 11.94 | - | - | Upgrade
|
| PB Ratio | 3.03 | 1.43 | 1.73 | 2.22 | - | - | Upgrade
|
| P/TBV Ratio | 3.08 | 1.45 | 1.75 | 2.25 | - | - | Upgrade
|
| P/OCF Ratio | 173.56 | 106.70 | 20.48 | 103.06 | - | - | Upgrade
|
| EV/Sales Ratio | 14.77 | 5.63 | 6.09 | 8.42 | - | - | Upgrade
|
| EV/EBITDA Ratio | - | - | 25.67 | 32.80 | - | - | Upgrade
|
| EV/EBIT Ratio | - | - | 43.75 | 49.28 | - | - | Upgrade
|
| Debt / Equity Ratio | 0.03 | 0.04 | - | - | 0.13 | 0.02 | Upgrade
|
| Debt / EBITDA Ratio | - | - | - | - | 0.48 | 0.08 | Upgrade
|
| Debt / FCF Ratio | - | - | - | - | - | 0.15 | Upgrade
|
| Net Debt / Equity Ratio | -0.43 | -0.49 | -0.60 | -0.62 | 0.10 | -0.08 | Upgrade
|
| Net Debt / EBITDA Ratio | 38.18 | 45.49 | -13.88 | -13.08 | 0.36 | -0.29 | Upgrade
|
| Net Debt / FCF Ratio | 5.30 | 4.10 | 41.84 | 8.74 | -0.91 | -0.57 | Upgrade
|
| Asset Turnover | 0.16 | 0.14 | 0.17 | 0.27 | 0.68 | 0.69 | Upgrade
|
| Inventory Turnover | 1.60 | 1.56 | 1.67 | 1.75 | 2.66 | 3.11 | Upgrade
|
| Quick Ratio | 6.23 | 5.97 | 8.69 | 14.99 | 0.76 | 1.59 | Upgrade
|
| Current Ratio | 7.38 | 6.84 | 9.58 | 16.88 | 1.53 | 2.49 | Upgrade
|
| Return on Equity (ROE) | -2.35% | -1.25% | 4.05% | 7.75% | 20.28% | 29.31% | Upgrade
|
| Return on Assets (ROA) | -1.99% | -1.79% | 1.51% | 2.92% | 11.51% | 11.79% | Upgrade
|
| Return on Invested Capital (ROIC) | -6.44% | -6.72% | 5.76% | 8.80% | 19.45% | 20.95% | Upgrade
|
| Return on Capital Employed (ROCE) | -3.50% | -3.10% | 2.50% | 3.20% | 20.90% | 21.90% | Upgrade
|
| Earnings Yield | -0.80% | -0.92% | 2.31% | 2.17% | - | - | Upgrade
|
| FCF Yield | -2.70% | -8.43% | -0.83% | -3.22% | - | - | Upgrade
|
| Dividend Yield | 0.47% | 1.00% | 0.80% | 0.61% | - | - | Upgrade
|
| Payout Ratio | - | - | 31.89% | 41.12% | 31.20% | 18.85% | Upgrade
|
| Buyback Yield / Dilution | 0.87% | 1.75% | -2.12% | -30.56% | 0.00% | -9.67% | Upgrade
|
| Total Shareholder Return | 1.34% | 2.75% | -1.32% | -29.96% | 0.00% | -9.67% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.